Gabriel Musso, Ph.D., BioSymetrics Inc.

Gabriel Musso, Ph.D. As CSO and head of Life Sciences, Gabe is expanding BioSymetrics’ scientific leadership in our key healthcare and biomedical markets for our Augusta™ platform, in areas such as biopharma R&D informatics, precision medicine, drug compound HTL generation, genomics, imaging and clinical diagnosis. Previously, Gabe was an Associate Scientist at Brigham and Women’s Hospital where his work focused on using machine learning frameworks to predict gene and small molecule function, and identification of disease-causal genes using large-scale genomic datasets. Gabe received his Ph.D. in Molecular Genetics from the University of Toronto. He also received his Masters of Science and undergraduate degrees from the University of Toronto.


10:05 AM - 10:35 AM

AI Applications for Identifying New Drug Candidates

Your CEO knows the company needs to adopt AI/ML technology, but they don't want to get involved in the details.  You now have the budget, but you need to produce an ROI.  What are your options when it comes to using AI tools to identify new drug candidates?  AI has the potential to become an indispensable tool but only if the near-term ROI is realized.  What questions do you need to ask to get this right and make a difference in speed, cost and outcomes?



  • Adam West

    Adam West Director, Research Data Sciences and Engineering Eli Lilly and Company

Download Latest Agenda